Tribalights Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 20 Road 2050, Aztec, NM 87410 Phone: 310-721-4398 |
Center For Valued Living, Pllc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 113 W Chaco St, Aztec, NM 87410 Phone: 720-347-8559 Fax: 720-207-6885 |
Focused Solutions Counseling, Llc Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 218 E. Chuska, Aztec, NM 87410 Phone: 505-333-7042 Fax: 505-333-7043 |
Therapeutic Solutions Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 2325 W Aztec Blvd, Po B0x 306, Aztec, NM 87410 Phone: 970-946-4254 |
Aztec Municipal School District Social Worker - School Medicare: Not Enrolled in Medicare Practice Location: 1607 W Aztec Blvd, Aztec, NM 87410 Phone: 505-334-3695 |
Small Epiphanies, Inc. Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 106 S Main Ave, Aztec, NM 87410 Phone: 505-334-4919 Fax: 505-334-4916 |
News Archive
Medisse, a medical device company focused on the development of a new generation of resorbable flexible implants, announced today that it has successfully completed the biocompatibility evaluation of its novel resorbable FlexiSurge biomaterial in accordance with the international ISO 10993 standards.
Mechanical ventilation can be a lifesaver for patients suffering from lung disorders such as chronic obstructive pulmonary disease, asthma and pneumonia. Unfortunately, the use of ventilators to support breathing can cause further lung injury, particularly in elderly patients.
About 12 percent of patients who receive implantable cardiac devices such as a pacemaker or defibrillator and fill an opioid prescription after surgery will consistently use the pain medication in the months afterward, raising the potential for addiction following these common procedures and identifying another pathway that could contribute to the national opioid crisis, according to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania.
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced commencement of a Phase 2 study of a d-Amphetamine Transdermal System (d-ATS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Currently, there is no approved amphetamine-based transdermal treatment option available for ADHD.
› Verified 3 days ago